康缘药业
(600557)
| 流通市值：76.36亿 | | | 总市值：76.80亿 |
| 流通股本：5.78亿 | | | 总股本：5.82亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,109,535,857.51 | 2,259,796,227.6 | 1,359,020,285.93 | 4,867,806,702.4 |
| 营业收入 | 3,109,535,857.51 | 2,259,796,227.6 | 1,359,020,285.93 | 4,867,806,702.4 |
| 二、营业总成本 | 2,769,653,537.12 | 1,996,276,733.86 | 1,187,013,990.73 | 4,359,915,092.72 |
| 营业成本 | 802,158,552.41 | 575,231,266.78 | 345,110,322.75 | 1,252,521,178.25 |
| 税金及附加 | 49,261,258.24 | 35,294,055.43 | 21,545,793.11 | 74,782,203.45 |
| 销售费用 | 1,177,466,926.09 | 854,434,478.61 | 508,857,832.21 | 1,936,943,796.67 |
| 管理费用 | 292,466,648.29 | 210,086,533.86 | 116,513,658.07 | 347,037,709.33 |
| 研发费用 | 466,741,332.21 | 339,195,413.76 | 204,124,846.95 | 771,690,071.27 |
| 财务费用 | -18,441,180.12 | -17,965,014.58 | -9,138,462.36 | -23,059,866.25 |
| 其中:利息收入 | 18,807,106.48 | 18,269,273.17 | 9,327,632.67 | 24,454,690.7 |
| 加:投资收益 | 10,263,953.22 | 6,114,952.49 | 6,033,417.99 | 14,794,029.67 |
| 资产处置收益 | 703,685.04 | 703,685.05 | -55,324.11 | 757,741.43 |
| 资产减值损失(新) | - | - | - | -2,771,458.16 |
| 信用减值损失(新) | 490,394.26 | -467,888.64 | -690,851.09 | -120,013.6 |
| 其他收益 | 70,960,741.08 | 42,640,880.99 | 5,301,145.82 | 43,240,484.2 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 422,301,093.99 | 312,511,123.63 | 182,594,683.81 | 563,792,393.22 |
| 加:营业外收入 | 11,776,485.18 | 10,809,360.42 | 954,064.37 | 6,155,189.18 |
| 减:营业外支出 | 6,818,856.27 | 6,508,013.46 | 5,947,210.04 | 18,964,979.03 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 427,258,722.9 | 316,812,470.59 | 177,601,538.14 | 550,982,603.37 |
| 减:所得税费用 | 63,275,423.14 | 45,517,387.72 | 28,033,953.26 | 3,932,331.59 |
| 六、净利润 | 363,983,299.76 | 271,295,082.87 | 149,567,584.88 | 547,050,271.78 |
| 持续经营净利润 | 363,983,299.76 | 271,295,082.87 | 149,567,584.88 | 547,050,271.78 |
| 归属于母公司股东的净利润 | 357,144,879.13 | 265,423,194.43 | 148,044,958.72 | 536,732,878.37 |
| 少数股东损益 | 6,838,420.63 | 5,871,888.44 | 1,522,626.16 | 10,317,393.41 |
| (一)基本每股收益 | 0.62 | 0.46 | 0.26 | 0.93 |
| (二)稀释每股收益 | 0.62 | 0.46 | 0.25 | 0.93 |
| 九、综合收益总额 | 363,983,299.76 | 271,295,082.87 | 149,567,584.88 | 547,050,271.78 |
| 归属于母公司股东的综合收益总额 | 357,144,879.13 | 265,423,194.43 | 148,044,958.72 | 536,732,878.37 |
| 归属于少数股东的综合收益总额 | 6,838,420.63 | 5,871,888.44 | 1,522,626.16 | 10,317,393.41 |
| 公告日期 | 2024-10-31 | 2024-07-27 | 2024-04-13 | 2024-03-11 |
| 审计意见(境内) | | | | 标准无保留意见 |